Reportlinker Adds Benign Prostatic Hyperplasia - Drug Pipeline Analysis and Market Forecasts to 2016
NEW YORK, April 1 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Benign Prostatic Hyperplasia - Drug Pipeline Analysis and Market Forecasts to 2016
Benign Prostatic Hyperplasia - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
GlobalData, the industry analysis specialist's new report, "Benign Prostatic Hyperplasia– Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global benign prostatic hyperplasia market. The report identifies the key trends shaping and driving the global benign prostatic hyperplasia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global benign prostatic hyperplasia sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges in the global benign prostatic hyperplasia market. The Scope of the report includes:
- Annualized global benign prostatic hyperplasia revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global benign prostatic hyperplasia market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with benign prostatic hyperplasia.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global benign prostatic hyperplasia market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global benign prostatic hyperplasia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Benign Prostatic Hyperplasia Market: Market Characterization 6
2.1 Overview 6
2.2 Benign Prostatic Hyperplasia Market Size 6
2.3 Benign Prostatic Hyperplasia Market Forecast and CAGR 6
2.4 Drivers and Barriers for the Benign Prostatic Hyperplasia Market 7
2.4.1 Drivers for the Benign Prostatic Hyperplasia Market 8
2.4.2 Barriers for the Benign Prostatic Hyperplasia Market 8
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 10
3 Benign Prostatic Hyperplasia Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profiles of the Major Marketed Products in the Benign Prostatic Hyperplasia Market 12
3.3.1 Duodart (Fixed Dose Combination of Avodart and tamsulosin) 12
3.3.2 Alfuzosin (Xatral, Uroxatral) 13
3.3.3 Tamsulosin (Flomax, Harnal) 14
3.3.4 Terazosin (Hytrin) 16
3.3.5 Finasteride (Proscar) 17
3.3.6 Doxazosin (Cardura, Cardura XL) 18
3.3.7 Dutasteride (Avodart) 19
3.3.8 Silodosin (Rapaflo / Urief) 20
3.4 Key Takeaway 22
4 Benign Prostatic Hyperplasia Market: Pipeline Assessment 23
4.1 Overview 23
4.2 Strategic Pipeline Assessment 23
4.2.1 Technology Trends Analytic Framework 23
4.3 Benign Prostatic Hyperplasia Therapeutics – Promising Drugs under Clinical Development 25
4.4 Molecule Profile for Promising Drugs under Clinical Development 25
4.4.1 Cialis (Tadalafil) 25
4.4.2 NX-1207 26
4.4.3 PRX302 27
4.5 Benign Prostatic Hyperplasia Therapeutics Market – Clinical Pipeline by Mechanism of Action 28
4.6 Benign Prostatic Hyperplasia Pipeline – Pipeline by Clinical Phases of Development 29
4.6.1 Benign Prostatic Hyperplasia Therapeutics – Regulatory Filing and Phase III Clinical Pipeline 30
4.6.2 Benign Prostatic Hyperplasia Therapeutics – Phase II Clinical Pipeline 30
4.6.3 Benign Prostatic Hyperplasia Therapeutics –Phase I Clinical Pipeline 30
4.6.4 Benign Prostatic Hyperplasia Therapeutics – Preclinical and Discovery Clinical Pipeline 31
4.6.5 Discontinued / Suspended Drugs for Benign Prostatic Hyperplasia 31
4.7 Key Takeaway 31
5 Benign Prostatic Hyperplasia Market: Implications for Future Market Competition 32
6 Benign Prostatic Hyperplasia Market: Future Players in the Benign Prostatic Hyperplasia Market 33
6.1 Introduction 33
6.2 Eli Lilly and Company 34
6.2.1 Company Overview 34
6.2.2 Business Description 34
6.2.3 Genitourinary Pipeline Product Portfolio 34
6.2.4 Benign Prostatic Hyperplasia Product Portfolio 34
6.3 Nippon Shinyaku Co. Ltd 35
6.3.1 Company Overview 35
6.3.2 Business Description 36
6.3.3 Genitourinary Pipeline Product Portfolio 36
6.3.4 Benign Prostatic Hyperplasia Product Portfolio 36
6.4 Nymox Pharmaceutical Corporation 36
6.4.1 Company Overview 36
6.4.2 Business Description 37
6.4.3 Genitourinary Pipeline Product Portfolio 37
6.4.4 Benign Prostatic Hyperplasia Product Portfolio 37
6.5 Protox Therapeutics, Inc. 38
6.5.1 Company Overview 38
6.5.2 Business Description 38
6.5.3 Genitourinary Pipeline Product Portfolio 38
6.5.4 Benign Prostatic Hyperplasia Product Portfolio 38
6.6 Light Sciences Oncology, Inc. 39
6.6.1 Company Overview 39
6.6.2 Business Description 39
6.6.3 Genitourinary Pipeline Product Portfolio 40
6.6.4 Benign Prostatic Hyperplasia Product Portfolio 40
7 Benign Prostatic Hyperplasia Market: Appendix 41
7.1 Market Definition 41
7.2 Abbreviations 41
7.3 Research Methodology 42
7.3.1 Coverage 42
7.3.2 Secondary Research 43
7.3.3 Forecasting 43
7.3.4 Primary Research 46
7.3.5 Expert Panels 46
7.4 Contact Us 46
7.5 Disclaimer 46
7.6 Sources 47
1.1 List of Tables
Table 1: Global Benign Prostatic Hyperplasia Market Revenues ($m), 2001–2009 7
Table 2: Global Benign Prostatic Hyperplasia Market Forecast ($m), 2009–2016 7
Table 3: Major Marketed Products Comparison in the Benign Prostatic Hyperplasia Market, 2010 21
Table 4: Benign Prostatic Hyperplasia Therapeutics – Most Promising Drugs under Clinical Development, 2010 25
Table 5: Benign Prostatic Hyperplasia Therapeutics –Regulatory Filing and Phase III Clinical Pipeline, 2010 30
Table 6: Benign Prostatic Hyperplasia Therapeutics –Phase II Clinical Pipeline, 2010 30
Table 7: Benign Prostatic Hyperplasia Therapeutics –Phase I Clinical Pipeline, 2010 30
Table 8: Benign Prostatic Hyperplasia Therapeutics –Preclinical and Discovery Pipeline, 2010 31
Table 9: List of Discontinued Drugs for Benign Prostatic Hyperplasia, 2010 31
Table 10: Eli Lilly and Company – Genitourinary Pipeline, 2010 34
Table 11: Nippon Shinyaku Co. Ltd– Genitourinary Pipeline, 2010 36
Table 12: Nymox Pharmaceutical Corporation – Genitourinary Pipeline, 2010 37
Table 13: Protox Therapeutics, Inc. – Genitourinary Pipeline, 2010 38
Table 14: Light Sciences Oncology, Inc. – Genitourinary Pipeline, 2010 40
1.2 List of Figures
Figure 1: Global Benign Prostatic Hyperplasia Market Revenues ($m), 2001–2009 6
Figure 2: Global Benign Prostatic Hyperplasia Market Forecast ($m), 2009–2016 7
Figure 3: Opportunity and Unmet Need in the Benign Prostatic Hyperplasia Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Marketed Products for Benign Prostatic Hyperplasia, 2010 12
Figure 5: Technology Trends Analytic Framework of the Benign Prostatic Hyperplasia Pipeline, 2010 24
Figure 6: Technology Trends Analytic Framework of the Benign Prostatic Hyperplasia Pipeline – Description, 2010 24
Figure 7: Benign Prostatic Hyperplasia Therapeutics Market – Clinical Pipeline by Mechanism of Action (%), 2010 29
Figure 8: Benign Prostatic Hyperplasia Pipeline by Phase of Clinical Development, 2010 29
Figure 9: Implications for Future Market Competition in the Benign Prostatic Hyperplasia Market, 2010 32
Figure 10: Benign Prostatic Hyperplasia Therapeutics Market – Clinical Pipeline by Company (Number of Molecules), 2010 33
Figure 11: GlobalData Methodology 42
Figure 12: GlobalData Market Forecasting Model 45
Companies mentioned
Eli Lilly and Company
Nippon Shinyaku Co. Ltd
Nymox Pharmaceutical Corporation
Protox Therapeutics, Inc.
Light Sciences Oncology, Inc.
To order this report:
Pharmaceutical Industry: Benign Prostatic Hyperplasia - Drug Pipeline Analysis and Market Forecasts to 2016
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article